title: Long-term response to pazopanib in an elderly man with mRCC. A case report.
abstract: In recent years, the therapeutic scenario of metastatic renal cell carcinoma (mRCC) has been enriched by several new drugs that have revolutionized the natural history of this cancer. Pazopanib, an oral angiogenesis inhibitor, was recently approved for first-line and post-cytokine treatment of mRCC. The choice of the best first-line medical therapy is now the main clinical problem to be addressed. The decision-making is influenced by various factors: the results of pivotal trials including published face-to-face studies, the patient's medical history, and the safety profile of the drug. We present a case report of a long-surviving elderly man with mRCC who did not undergo a cytoreductive nephrectomy and was treated with pazopanib.
authors: Carmine
authors: C
authors: D'Aniello
authors: Carla
authors: C
authors: Cavaliere
authors: Salvatore
authors: S
authors: Pisconti
authors: Gaetano
authors: G
authors: Facchini
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy; D007037:Hypothyroidism / Q000139:chemically induced / Q000188:drug therapy; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D012540:Scapula; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib